Open Access
Review

CARD9 as a potential therapeutic target in lung cancer

Ruanmei Sheng1,2,Zhiwen Yang3,*
1
Department of Emergency Medicine and Intensive Care, Shanghai Songjiang District Central Hospital, 201600 Shanghai, China
2
Department of Emergency Medicine and Intensive Care, Shanghai Songjiang Clinical Medical College of Nanjing Medical University, 201600 Shanghai, China
3
Department of Pharmacy, Shanghai Songjiang District Central Hospital, 201600 Shanghai, China
DOI: 10.52586/5055 Volume 26 Issue 12, pp.1621-1626
Submited: 28 August 2021 Revised: 17 November 2021
Accepted: 19 November 2021 Published: 30 December 2021
Copyright: © 2021 The author(s). Published by BRI. This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Caspase recruitment domain-containing protein 9 (CARD9) is highly expressed in myeloid cells and has been identified as a central regulator of innate immunity. Increasingly, studies demonstrate that CARD9 also plays a critical role in the development of lung cancer. This review focuses on the clinical significance and potential molecular mechanisms that CARD9 plays in lung cancer.

Key words

CARD9; Lung cancer; Clinical significance; Molecular mechanism; Therapy target

Share and Cite
Ruanmei Sheng, Zhiwen Yang. CARD9 as a potential therapeutic target in lung cancer. Frontiers in Bioscience-Landmark. 2021. 26(12); 1621-1626.